IQVIA (IQV) Set to Announce Quarterly Earnings on Thursday

IQVIA (NYSE:IQV) is set to announce its earnings results before the market opens on Thursday, October 31st. Analysts expect the company to announce earnings of $2.57 per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

IQVIA (NYSE:IQV) last announced its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The firm had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. During the same quarter in the previous year, the company posted $2.22 EPS. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. On average, analysts expect IQVIA to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.

IQVIA Trading Up 0.0 %

Shares of IQV stock opened at $228.31 on Thursday. The firm has a 50-day moving average price of $238.71 and a 200 day moving average price of $230.92. IQVIA has a twelve month low of $167.42 and a twelve month high of $261.73. The company has a market capitalization of $41.62 billion, a price-to-earnings ratio of 29.65, a PEG ratio of 2.26 and a beta of 1.49. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80.

Analysts Set New Price Targets

Several brokerages recently weighed in on IQV. UBS Group boosted their target price on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. JPMorgan Chase & Co. cut their target price on IQVIA from $288.00 to $279.00 and set an “overweight” rating on the stock in a research report on Wednesday. Barclays dropped their price target on IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a research note on Tuesday, October 15th. Truist Financial dropped their target price on shares of IQVIA from $300.00 to $286.00 and set a “buy” rating for the company in a research report on Monday, October 14th. Finally, Argus raised shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $267.27.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.60% of the stock is currently owned by insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.